Pore et al., 2021 - Google Patents
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non–small cell lung cancer and is …Pore et al., 2021
View HTML- Document ID
- 4368179439877199926
- Author
- Pore N
- Wu S
- Standifer N
- Jure-Kunkel M
- de Los Reyes M
- Shrestha Y
- Halpin R
- Rothstein R
- Mulgrew K
- Blackmore S
- Martin P
- Meekin III J
- Griffin M
- Bisha I
- Proia T
- Miragaia R
- Herbst R
- Gupta A
- Abdullah S
- Raja R
- Frigault M
- Barrett J
- Dennis P
- Ascierto M
- Oberst M
- Publication year
- Publication venue
- Cancer Discovery
External Links
Snippet
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associated with resistance …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pore et al. | Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non–small cell lung cancer and is reversed by STAT3 knockdown | |
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Tu et al. | Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC | |
| Sharma et al. | LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy | |
| de Streel et al. | Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer | |
| Bedognetti et al. | Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop | |
| Eschweiler et al. | Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy | |
| Dushyanthen et al. | Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer | |
| Gide et al. | Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy | |
| Trujillo et al. | T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection | |
| Gettinger et al. | Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer | |
| Yu et al. | Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma | |
| Prat et al. | Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma | |
| Qin et al. | Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib | |
| Adeegbe et al. | BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non–small cell lung cancer | |
| Brea et al. | Kinase regulation of human MHC class I molecule expression on cancer cells | |
| Nowak et al. | Immunoregulatory functions of VISTA | |
| Baer et al. | Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity | |
| Lim et al. | The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma | |
| Jackson et al. | Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma | |
| Zeng et al. | Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion | |
| Kashima et al. | Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer | |
| Itahashi et al. | BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors | |
| Klepsch et al. | Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade | |
| Trinquand et al. | Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia |